Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
about
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemiaAn update of current treatments for adult acute myeloid leukemiaMinimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsOutcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant.Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia.Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.Cord-Blood Transplantation in Patients with Minimal Residual DiseaseGemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningComparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantationAcute myeloid leukemia: 2014 update on risk-stratification and management.Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.A multigene array for measurable residual disease detection in AML patients undergoing SCTMinimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation.Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT.Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemiaThe dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?Relapse assessment following allogeneic SCT in patients with MDS and AML.A critical review of which children with acute myeloid leukaemia need stem cell procedures.How I treat paediatric relapsed acute myeloid leukaemia.Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.Minimal residual disease in acute myeloid leukemia--current status and future perspectives.Frontline treatment of acute myeloid leukemia in adults.Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.
P2860
Q26771438-F08B96D6-0B52-4B97-8B79-32E01A4FCCF5Q26776396-27959776-C187-40DD-A9F3-20403D8F301CQ28073464-970DD184-0D41-4438-B53E-D86E058FCC89Q30240140-EB2465DA-8BB1-471D-98C5-2FDA474E1D3CQ33831349-39F5117C-C8F1-4938-B51A-3FB14457B9DFQ33832709-B5507897-B2DD-44CB-B265-003F3B55B820Q33868700-3B0F3DF8-1EDB-4B37-A378-453EDBCD18B5Q33911314-B9535577-FBF6-4FEB-ACA7-EE75B36BEC48Q34172042-EE7CD354-4105-4185-9B9B-33FEEEFA2FEAQ34325183-F8E277BC-9978-4A20-BD15-B1E2A056BA09Q34364350-6F5B2E21-4D02-4585-B5E8-61770B3B2CE4Q34380489-254A9170-0989-4BB5-B92D-51127F8E2464Q34402494-FC8CF9F5-5F44-4166-B2E5-1F7C3207E392Q34627218-0489BA4C-9374-4868-9C9D-8E2C953F2344Q34665691-8046C7AA-463C-42F0-A494-4C7055754C69Q34684038-C60A34EF-4D00-4D36-97F5-92EDD60A11F5Q34979564-F9702700-FB5E-4EB1-8EA0-7EF09200C5C5Q35546759-F5230B51-B3E2-4FA4-B9DD-165ED827F57EQ35582360-2133D9F9-339B-400A-AADA-F938ACA2A528Q35992927-8BF69DE7-336A-4502-9994-AEFC56BF30D4Q36040293-ECC1AED3-22F1-4C22-B099-7CE3541D2C11Q36478979-AE50C43E-532B-4602-82D4-C10A2847485BQ36483114-8331C2BA-3845-40E3-B2B0-4C1F06617E71Q36673472-8749CF28-A41B-47D6-8B4F-07AC320FDCF9Q36716744-4B591460-D910-41A5-B075-98ACA77FE9ABQ36914475-6D21DB45-8959-4126-9AE0-C679AB7790A7Q37072126-A53B27AD-DD82-4FD1-A3DC-A031B60C1F6BQ37084121-31D81060-4AD0-4CA3-98D4-2A39668A8E6AQ37270982-19FAC41B-8CDB-40F1-9417-825E6BBB8958Q37628021-9E9FADB4-F764-465D-A5C7-9672401B5A49Q37718826-D45AEDA0-95DF-40B3-BC8B-69CFBBD4D4DBQ38199056-28ADB561-DB83-4E3C-B13C-EFB5AE18D5F8Q38199623-127486FA-D92C-4B43-B873-5BEE9A0F1366Q38205864-647534E8-B053-4AF0-AFEE-8B214954E5E5Q38212509-BA0D5536-58D5-410C-B2BE-EA291DD1BA2DQ38212956-BB5D9A8C-31DF-4EA7-A752-8471AFFD2119Q38438814-119EDAD4-D8FE-490A-BD8E-88E8B37CDBBEQ38494659-E25E3BA5-6F9B-4C73-85F4-B6D53657E6A7Q38767583-0CDDBBCC-C3DF-46D4-85C3-93E723EB4FE1Q38792016-958B1BA9-C850-4304-9FE1-F85C13710133
P2860
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Significance of minimal residu ...... and second complete remission.
@en
Significance of minimal residu ...... and second complete remission.
@nl
type
label
Significance of minimal residu ...... and second complete remission.
@en
Significance of minimal residu ...... and second complete remission.
@nl
prefLabel
Significance of minimal residu ...... and second complete remission.
@en
Significance of minimal residu ...... and second complete remission.
@nl
P2093
P2860
P50
P1433
P1476
Significance of minimal residu ...... and second complete remission.
@en
P2093
Boglarka Gyurkocza
Brent L Wood
Colleen Delaney
Elihu H Estey
Jerald P Radich
John M Pagel
Roland B Walter
Sarah A Buckley
P2860
P304
P356
10.1182/BLOOD-2013-06-506725
P407
P577
2013-07-11T00:00:00Z